Abdominal Aortic Aneurysm Repair Outcomes For Seniors Reviewed A new study published in the Society for Vascular Surgery's October 2009 issue of the Journal of Vascular Surgery reports that the elderly have better operative outcomes when endovascular repair, rather than open surgery, is used to treat an abdominal aortic aneurysm (AAA).
Source: www.medicalnewstoday.comOnyx Pharmaceuticals Initiates Phase 1 Study Of ONX 0801 In Advanced Solid Tumors Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase (TS) inhibitor, as a potential treatment for advanced solid tumors. This open-label, dose-finding study will evaluate the safety and pharmacokinetics of ONX 0801 in patients with advanced solid tumors.
Source: www.medicalnewstoday.comSorafenib/Capecitabine Combo Boosts Progression-Free Survival In Advanced Breast Cancer BERLIN - The potent oral multiple kinase inhibitor sorafenib (NexavarR) combined with the chemotherapy drug capecitabine (XelodaR) significantly improves progression-free survival (PFS) over capecitabine alone in patients with locally advanced or metastatic HER-2 negative breast cancer, according to
Source: www.medicalnewstoday.comBioCryst Announces Initiation Of Phase 2 Study Of BCX4208 For The Treatment Of Gout BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout. The gout trial is expected to enroll up to 120 subjects. "Over the last few decades gout has markedly increased in incidence and prevalence, both in the U.S. and elsewhere.
Source: www.medicalnewstoday.comUse Of Diabetes Drug Linked To Higher Risk Of Bone Fractures The findings of a study published recently in the open access journal, PLoS Medicine, suggest that there is a link between a type of drug introduced in the 1990s to treat type 2 diabetes (thiazolidinediones) and bone fracture. The study is the work of Ian Douglas of the London School of Hygiene and Tropical Medicine and colleagues.
Source: www.medicalnewstoday.comMedication Can Hasten Bone Loss Q: I take the acid blocker Nexium and expect that I will need to take it indefinitely. Does this increase my risk of osteoporosis? Are there other drugs that increase the risk of osteoporosis? A: It’s not clear if the long-term use of esomeprazole (Nexium) will increase your risk of osteoporosis. Some studies link drugs in the [...]
Source: feedproxy.google.comInterMune Announces Initiation Of Ritonavir-Boosted ITMN-191/RG7227 Study In HCV Patients InterMune, Inc. (Nasdaq: ITMN) announced that its partner Roche has begun dosing in a Phase 1b multiple ascending dose (MAD) study of ITMN-191 (RG7227) boosted by low-dose ritonavir in patients chronically infected with hepatitis C virus (HCV) genotype-1. Ritonavir boosting is an option to enhance and improve pharmacokinetic profiles of protease inhibitors.
Source: www.medicalnewstoday.com
# posted by Network @ 1:36 PM
